Structure Therapeutics Director Gets 42,833 Stock Options at $7.37 Strike Price

Structure Therapeutics (GPCR) Director Russell Angus C. received a stock option grant on June 23, 2025, representing a significant insider transaction.

Accepted by SEC EDGAR 06/25/2025 - 05:45 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Structure Therapeutics (GPCR) Director Russell Angus C. received a stock option grant on June 23, 2025, representing a significant insider transaction. The grant consists of 42,833 share options with the following key terms:

• Exercise price: $7.37 per share, based on fair market value of Ordinary Shares
• Vesting schedule: Equal monthly installments over 12 months from June 23, 2025
• Full vesting: Prior to 2026 annual shareholder meeting
• Expiration date: June 22, 2035
• Each ADS (American Depositary Share) represents 3 Ordinary Shares

This equity compensation grant aligns with standard director compensation practices and demonstrates long-term commitment to the company. The 10-year exercise window provides significant time value for the options.

Insider Trade Summary

Grant/Award: 42,833 shares

Grant/Award 1 txn

Insider Russell Angus C.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Share Option (right to buy)	42,833	$0.00	$0.00

Holdings After Transaction: Share Option (right to buy) — 42,833 contracts (Direct)

Holdings Before and After: Share Option (right to buy), 0 to 42,833 contracts (Direct)

Footnotes (3)

1. F1. The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs").
2. F2. The shares vest in equal monthly installments over the 12 months following June 23, 2025, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2026 annual shareholder meeting,
3. F3. The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock options were granted to Director Russell Angus C. of GPCR on June 23, 2025?

Director Russell Angus C. was granted 42,833 share options with an exercise price of $7.37 per share. These options expire on June 22, 2035 and represent the right to buy GPCR ordinary shares.

What is the vesting schedule for GPCR Director Russell's June 2025 stock options?

The stock options vest in equal monthly installments over 12 months following June 23, 2025. However, the grant will become fully vested immediately prior to GPCR's 2026 annual shareholder meeting, regardless of the monthly vesting schedule.

How many ordinary shares are represented by each GPCR ADS (American Depositary Share)?

Each American Depositary Share (ADS) of Structure Therapeutics (GPCR) represents three Ordinary Shares of the company.

What was the exercise price of GPCR's stock options granted to Director Russell and how was it determined?

The exercise price was set at $7.37 per share, which equals the fair market value per Ordinary Share on the grant date, based on the trading price of GPCR's American Depositary Shares (ADSs).

When did GPCR Director Russell Angus C. file this Form 4?

The Form 4 was filed on June 25, 2025, two days after the stock option grant transaction date of June 23, 2025, and was signed by Jun Yoon as Attorney-in-Fact.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Russell Angus C.

(Last) (First) (Middle)

C/O STRUCTURE THERAPEUTICS INC.

601 GATEWAY BLVD., SUITE 900

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [ GPCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	$7.37(1)	06/23/2025		A		42,833		(2)	06/22/2035	Ordinary Shares	42,833(3)	$0	42,833	D

Explanation of Responses:

1. The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs").

2. The shares vest in equal monthly installments over the 12 months following June 23, 2025, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2026 annual shareholder meeting,

3. The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.

	/s/ Jun Yoon, Attorney-in-Fact	06/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.